Cullinan Therapeutics Inc [CGEM] stock prices are up 1.26% to $20.16 at the moment. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The CGEM shares have gain 10.22% over the last week, with a monthly amount glided 22.18%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Cullinan Therapeutics Inc [NASDAQ: CGEM] stock has seen the most recent analyst activity on May 01, 2024, when Stifel initiated its Buy rating and assigned the stock a price target of $40. On February 15, 2024, Wedbush initiated with a Outperform rating and assigned a price target of $30 on the stock. TD Cowen started tracking the stock assigning a Outperform rating. BTIG Research initiated its recommendation with a Buy and recommended $20 as its price target on November 21, 2022. Morgan Stanley upgraded its rating to Overweight for this stock on April 27, 2021, but kept the price target unchanged to $40. In a note dated February 02, 2021, SVB Leerink initiated an Outperform rating and provided a target price of $52 on this stock.
The stock price of Cullinan Therapeutics Inc [CGEM] has been fluctuating between $7.64 and $30.19 over the past year. Currently, Wall Street analysts expect the stock to reach $25.67 within the next 12 months. Cullinan Therapeutics Inc [NASDAQ: CGEM] shares were valued at $20.16 at the most recent close of the market. An investor can expect a potential return of 27.33% based on the average CGEM price forecast.
Analyzing the CGEM fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.29, Equity is -0.29 and Total Capital is -0.4. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 19.66 points at the first support level, and at 19.16 for the second support level. However, for the 1st resistance point, the stock is sitting at 20.70, and for the 2nd resistance point, it is at 21.24.
Ratios To Look Out For
It’s worth pointing out that Cullinan Therapeutics Inc [NASDAQ:CGEM]’s Current Ratio is 20.33. In addition, the Quick Ratio stands at 20.33 and the Cash Ratio stands at 3.39.
Transactions by insiders
Recent insider trading involved Michaelson Jennifer, Chief Scientific Officer, that happened on Jul 05 ’24 when 8000.0 shares were sold. Chief Scientific Officer, Michaelson Jennifer completed a deal on May 07 ’24 to sell 5606.0 shares. Meanwhile, Chief Scientific Officer Michaelson Jennifer sold 58000.0 shares on May 06 ’24.
